Journal article
An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT
Abstract
BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll).
METHODS: The prospective interventional open-label bend-act trial evaluated bendamustine in patients with rituximab-refractory indolent nhl (inhl) and …
Authors
Kouroukis CT; Crump M; MacDonald D; Larouche JF; Stewart DA; Johnston J; Sauvageau S; Beausoleil E; Sage P; Dubois SG
Journal
Current Oncology, Vol. 22, No. 4, pp. 260–271
Publisher
MDPI
Publication Date
August 2015
DOI
10.3747/co.22.2431
ISSN
1198-0052